Navigation Links
Loxo Oncology And Array BioPharma Announce License And Collaboration Agreement
Date:7/10/2013

nd commercialization of its out-licensed drug candidates; Array's ability to continue to fund and successfully progress research and development efforts and to create effective, commercially viable drugs; Array's ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials; risks associated with Array's dependence on third-party service providers to successfully conduct clinical trials within and outside the United States; Array's ability to achieve and maintain profitability and maintain sufficient cash resources; the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities; Array's ability to out-license its proprietary candidates on favorable terms; Array's ability to attract and retain experienced scientists and management. This information is being provided as of July 10, 2013. Array undertakes no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.CONTACTS:

 Paul Laland (Loxo Oncology)(415) 946-1071 or plaland@brewlife.com Tricia Haugeto (Array BioPharma) (303) 386-1193 or thaugeto@arraybiopharma.com


'/>"/>
SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
2. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
3. PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
4. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
5. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
6. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
7. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
8. Genomic Health Announces Results of Ten Studies in Breast, Prostate and Colon Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. ViewRays Chief Medical Officer Honored by American Society for Radiation Oncology (ASTRO)
10. Amgen To Webcast Investor Meeting At Upcoming American Society Of Clinical Oncology Annual Meeting
11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... -- Biomedical Research Laboratories (BRL) ( www.brlscience.com ) announced ... 2014 Inc. 500 list of America,s fastest-growing companies. ... prestigious list and ranked among the most successful companies ... Laboratories, CEO. "Today,s announcement represents a major milestone for ... work and talent of our team. BRL has a ...
(Date:8/26/2014)... Mass. , Aug. 26, 2014 Acelleron Medical ... Eatontown, N.J ., is expanding.  Acelleron, a ... to form a new division, Acelleron Maternal Health & Wellness ... clients by providing a full range of resources for pregnant ... has been named the director of maternal wellness. Vecchi, the ...
(Date:8/26/2014)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and its associated pain, ... advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) ... more than 100,000 Americans. As this disease progresses, ... lose the ability to breathe, leading ultimately to ...
Breaking Medicine Technology:Biomedical Research Laboratories Named to Inc. 500 List of America's Fastest-Growing Companies 2Suzanne Vecchi Named Director of Newly Acquired Acelleron Maternal Health & Wellness 2Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF) 2Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF) 3
... DATATRAK International, Inc. (OTCQX: DATA), a technology and services ... trials industry, today announced that it has been awarded ... Organization (CRO) in India, with which the Company had ... order to execute a Phase II study for the ...
... 8, 2011 Vanda Pharmaceuticals Inc. (Nasdaq: ... has granted orphan drug designation for tasimelteon, an oral ... for Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals with ... the designation that the Committee for Orphan Medicinal Products ...
Cached Medicine Technology:DATATRAK Awarded First Study With Kreara Solutions 2DATATRAK Awarded First Study With Kreara Solutions 3Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 2Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 3Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 4
(Date:8/26/2014)... Hearing aids are not always covered ... holders to determine what their hearing care benefits are. ... health plans and has published benefit details on their website ... , The following is a list of insurances or agencies ... NYSHIP/ NYS Empire Plan - Hearing Aid Benefit is $1500 ...
(Date:8/26/2014)... August 27, 2014 Emerging and established ... and useful to those they serve – which includes ... blog at http://www.PerWickstrom.com and read his latest ... Leaders Maintain their Edge.” , “Leadership is ... and can therefore be assumed,” commented Per Wickstrom, who ...
(Date:8/26/2014)... August 27, 2014 There are a ... however the reality is cruel. Some people, especially ladies ... may not save enough money to be affluent. Today, ... delighted to announce its new catalog, Flash Deals (also ... bags, outdoor accessories and more from this company are ...
(Date:8/26/2014)... 27, 2014 Atlanta Hearing Associates ... Hearing Associates has expanded its professional staff to 6 audiologists. ... Stephanie Collins . Atlanta Hearing Associates prides itself ... display a passionate commitment to patient needs and keep themselves ... loss treatments. The practice has grown from 1 to 4 ...
(Date:8/26/2014)... (PRWEB) August 27, 2014 Private ... custom labeled nutritional dietary supplements and products has ... their 33rd annual Inc. 500|5000 list. This exclusive ... marks the second consecutive year for Private Label ... Dell, Yelp, GoPro, Bridger, Tough Mudder, Bowlmor and ...
Breaking Medicine News(10 mins):Health News:East End Hearing of Long Island Now Participating in Many Local Health Plans 2Health News:East End Hearing of Long Island Now Participating in Many Local Health Plans 3Health News:Per Wickstrom’s Latest Blog Post Provides 10 Tips to Help Leaders Maintain their Edge 2Health News:Become a Rich Person Right Away By Taking Advantage Of Fecbek.com's Flash Deals 2Health News:Atlanta Hearing Associates Needs New Audiologists to Its Professional Staff 2Health News:Atlanta Hearing Associates Needs New Audiologists to Its Professional Staff 3Health News:Private Label Nutraceuticals Honored by Inc. 5000 as One of Today’s Fastest Growing Private Companies in America with Three-Year Sales Growth of 620% 2Health News:Private Label Nutraceuticals Honored by Inc. 5000 as One of Today’s Fastest Growing Private Companies in America with Three-Year Sales Growth of 620% 3Health News:Private Label Nutraceuticals Honored by Inc. 5000 as One of Today’s Fastest Growing Private Companies in America with Three-Year Sales Growth of 620% 4
... poses dangers, researchers say , , TUESDAY, Dec. 23 (HealthDay ... adults in the United States combine over-the-counter medications with ... for potentially dangerous interactions, a new survey finds. , ... for more than 175,000 emergency department visits for adverse ...
... doesn,t fund procedure , , TUESDAY, Dec. 23 (HealthDay ... each year, because their states don,t cover the procedure ... case to be made that circumcisions can protect our ... of public policy at the University of California, Los ...
... major tissue damage or surgical intervention is an important ... established therapeutic measure for severe liver diseases, it would ... the regenerative process and if they depend on the ... The group led by Prof. Schlaak from the Department ...
... It might be possible to grow human blood ... new study at The Ohio State University Medical Center. ... issue of the journal Experimental Hematology , might ... and in quantities that can ease the chronically tight ...
... the mutation faced higher odds of heart attack, death, study ... variation can make younger heart attack patients more prone to ... receive the anti-clotting drug Plavix, researchers report. , The study ... The Lancet . , Plavix plus low-dose aspirin are often ...
... LANSING, Mich. Only 3 percent of kids, meals ... the first study to examine the nutrient quality of ... Michigan State University,s Sharon Hoerr, a food science and ... teamed up with economist Sharon O,Donnell and pediatrician Jason ...
Cached Medicine News:Health News:Drug Combinations Putting Seniors at Risk 2Health News:Drug Combinations Putting Seniors at Risk 3Health News:Drug Combinations Putting Seniors at Risk 4Health News:Circumcision Rates Too Low 2Health News:Molecular events involved in liver regeneration 2Health News:Bioreactors might solve blood-platelet supply problems 2Health News:Gene Ups Risk for Those on Blood-Thinner Plavix 2Health News:Gene Ups Risk for Those on Blood-Thinner Plavix 3Health News:Nutritious fast-food kids' meals are scarce, researchers find 2
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The CA method used on the Dade Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of calcium in serum....
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
Medicine Products: